Literature DB >> 19331765

Severe acquired toxoplasmosis caused by wild cycle of Toxoplasma gondii, French Guiana.

Bernard Carme1, Magalie Demar, Daniel Ajzenberg, Marie Laure Dardé.   

Abstract

From 1998 through 2006, 44 cases of severe primary toxoplasmosis were observed in French Guiana in immunocompetent adults. Toxoplasma gondii isolates exhibited an atypical multilocus genotype. Severe disease in humans may result from poor host adaptation to neotropical zoonotic strains of T. gondii circulating in a forest-based cycle.

Entities:  

Mesh:

Year:  2009        PMID: 19331765      PMCID: PMC2671434          DOI: 10.3201/eid1504.081306

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


French Guiana is a French territory in South America; the Amazon rain forest covers 92% of the territory. Toxoplasmosis is a cosmopolitan parasitic disease. It is usually benign in patients without immunosuppression, but in French Guiana, it is a major public health problem, mainly because of the high prevalence of AIDS and because of an emerging severe form of acquired toxoplasmosis in immunocompetent patients.

The Cases

Until 1998, only 2 cases of severe primary toxoplasmosis had been reported in French Guiana, in 1992 () and 1997 (). However, from 1998 through 2006, 44 cases occurred (–). All patients were immunocompetent (not HIV-infected) adults who had been hospitalized because of a marked, nonspecific, infectious syndrome. All patients had elevated and prolonged fever; most had weight loss, hepatic cytolysis, lymphadenopathy, headache, and pneumopathy. Other signs such as rash, retinochoroiditis, myocarditis, myositis, and neurologic disorders, may occur with toxoplasmosis, albeit infrequently. Prognosis is linked to lung involvement, which typically occurs 10–15 days after onset of fever and requires hospitalization. Approximately one third of patients with this severe form of disease experience respiratory distress and need to be in an intensive care unit. Unless specific treatment (sulfadiazine and pyrimethamine) is initiated quickly, death may occur. In these patients, acute toxoplasmosis was diagnosed by serologic tests, which suggested recent primary infection (substantial and rapid increase in immunoglobulin [Ig] G, associated with specific IgM, in 2 separate samples taken 1–2 weeks apart tested at the same time); by blood or bronchoalveolar lavage samples positive by PCR; and by absence of an alternative cause. Toxoplasma gondii strains, virulent in mice, were isolated in some cases. Microsatellite analysis performed on isolated strains or on toxoplasma DNA extracts showed that all isolates exhibited an atypical multilocus genotype, in contrast with strains usually described in Europe or North America. Most patients reported forest-related activities such as ingestion of surface water, consumption of undercooked game meat, and hunting. Of the 44 patients, 1 died; the others recovered after standard treatment. We recently described an outbreak of toxoplasmosis from late December 2003 through mid January 2004 involving 11 cases among the 38 inhabitants of a village in Suriname near the French Guiana border (). Using 8 microsatellite markers with a high power of discrimination, we described a unique multilocus genotype for 5 patients and demonstrated that only 1 strain was responsible for this outbreak (in at least 5 of 11 patients). However, the same strain was responsible for different clinical outcomes in each of the 11 patients: 2 cases were congenital and lethal, 9 cases occurred in immunocompetent adults (5 patients, 1 of whom died, had disseminated toxoplasmosis and needed hospitalization; and 4 had less severe disease with no life-threatening signs or need for hospitalization). Genetic susceptibility of the host to this unusually severe form of toxoplasmosis may explain in part the severity of symptoms, although we observed this disease in the different ethnic groups of French Guiana (Caucasians from inland France, Creoles, Amerindians, Bushinengé, and Brazilians).

Conclusions

Such a severe outcome in humans may be explained by poor host adaptation to emerging and highly virulent strains of T. gondii circulating in a forest-based cycle involving wild felids (definitive hosts) and their prey (intermediate hosts) (Figure). The high seroprevalence for noncarnivorous wild mammals in French Guiana, especially terrestrial animals such as deer, armadillos, pacas, and peccaries (), suggests oral exposure to oocysts eliminated by wild felids in the absence of domestic cats (). Wild felids are still numerous in French Guiana. Isolation of 1 genetically atypical Toxoplasma strain in a free-living jaguar (Panthera onca) is a further argument for the existence of a T. gondii wildlife cycle (). Sources of contamination are uncooked meat from hunted game and river water containing oocysts excreted by wild cats.
Figure

Transmission cycle of highly virulent strains of Toxoplasma gondii involving wild felids (definitive hosts) and their prey (intermediate hosts).

Transmission cycle of highly virulent strains of Toxoplasma gondii involving wild felids (definitive hosts) and their prey (intermediate hosts). In North America and in Western Europe, T. gondii has been considered to have a clonal population structure and low genetic diversity; >95% of strains belonged to 3 clonal lineages, types I, II (mainly), and III (). The greater genetic diversity of T. gondii in a wild and tropical environment, compared with the domestic environment, could be connected to the considerably higher diversity of hosts in the wild. In the neotropical rain forest, fauna are abundant and highly diverse; 560 species of mammals have been recorded (). A plurality of alleles is needed for T. gondii to colonize a maximum of ecological niches in such a diverse environment. Because little molecular assessment has been performed for T. gondii from asymptomatic infected persons in French Guiana, it is difficult to know what proportion of persons infected with the atypical strains found there have severe disease. In French Guiana, a wild cycle of T. gondii coexists with a domestic cycle, in which cats take a central role. Both cycles, wild and domestic, can even merge with the anthropization of the Amazonian forest. For the domestic cycle, there are 11 DNA samples (6 urban isolates from animals raised in captivity [3 cats and 3 monkeys] and 5 human isolates from patients with classical disease [2 AIDS patients with cerebral toxoplasmosis, 2 patients with congenital infections, and 1 patient with lymphadenopathy]). These samples have less allelic diversity than wild isolates. Recent studies that used multiple markers and collected samples from other countries have shown that, at least in the tropical part of South America, T. gondii strains have higher genetic diversity (,). Few data concerning the genetic diversity and population structure of this parasite are available in Africa () and Asia (). The number of cases of this severe form of primary T. gondii infection (>50 well-documented observations in the past decade) is particularly high in French Guiana, given the small size of the population (≈200,000 inhabitants), compared with the low number of published cases. Although such a wild T. gondii cycle with severe human clinical consequences has not been described in Brazil or in other countries of the Guyana Shield, it seems unlikely that it is a disease specific to French Guiana. Amazonian areas, and likely other rain forest areas where felids live, could be affected by this form of toxoplasmosis, which could be designated “Amazonian toxoplasmosis” or “wild rain forest toxoplasmosis.” From a healthcare perspective worldwide, physicians should consider a diagnosis of acute toxoplasmosis as soon as possible after the onset of signs and symptoms in patients who live in or have recently visited the Amazonian region and who have a severe infectious syndrome with visceral, especially lung, involvement. Serologic tests should be promptly submitted for such patients. If recent infection with T. gondii is diagnosed, a potent antitoxoplasmosis treatment (sulfadiazine plus pyrimethamine) must be prescribed without delay.
  12 in total

1.  Severe acquired toxoplasmosis in immunocompetent adult patients in French Guiana.

Authors:  B Carme; F Bissuel; D Ajzenberg; R Bouyne; C Aznar; M Demar; S Bichat; D Louvel; A M Bourbigot; C Peneau; P Neron; M L Dardé
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

2.  Ecologic correlates of Toxoplasma gondii exposure in free-ranging neotropical mammals.

Authors:  Benoit de Thoisy; Magalie Demar; Christine Aznar; Bernard Carme
Journal:  J Wildl Dis       Date:  2003-04       Impact factor: 1.535

3.  Genotyping studies of Toxoplasma gondii isolates from Africa revealed that the archetypal clonal lineages predominate as in North America and Europe.

Authors:  G V Velmurugan; J P Dubey; C Su
Journal:  Vet Parasitol       Date:  2008-05-10       Impact factor: 2.738

4.  Toxoplasma gondii-associated Guillain-Barré syndrome in an immunocompetent patient.

Authors:  P Bossi; E Caumes; L Paris; M L Dardé; F Bricaire
Journal:  J Clin Microbiol       Date:  1998-12       Impact factor: 5.948

5.  Genetic and biologic characterization of Toxoplasma gondii isolates of cats from China.

Authors:  J P Dubey; X Q Zhu; N Sundar; H Zhang; O C H Kwok; C Su
Journal:  Vet Parasitol       Date:  2007-01-30       Impact factor: 2.738

6.  Globalization and the population structure of Toxoplasma gondii.

Authors:  Tovi Lehmann; Paula L Marcet; Doug H Graham; Erica R Dahl; J P Dubey
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-18       Impact factor: 11.205

7.  Toxoplasma gondii comprises three clonal lineages: correlation of parasite genotype with human disease.

Authors:  D K Howe; L D Sibley
Journal:  J Infect Dis       Date:  1995-12       Impact factor: 5.226

8.  Genetic diversity, clonality and sexuality in Toxoplasma gondii.

Authors:  D Ajzenberg; A L Bañuls; C Su; A Dumètre; M Demar; B Carme; M L Dardé
Journal:  Int J Parasitol       Date:  2004-09       Impact factor: 3.981

9.  Fatal outbreak of human toxoplasmosis along the Maroni River: epidemiological, clinical, and parasitological aspects.

Authors:  Magalie Demar; Daniel Ajzenberg; Danielle Maubon; Félix Djossou; Dayanand Panchoe; Widya Punwasi; Nasser Valery; Christian Peneau; Jean-Louis Daigre; Christine Aznar; Benoit Cottrelle; Laurence Terzan; Marie-Laure Dardé; Bernard Carme
Journal:  Clin Infect Dis       Date:  2007-08-27       Impact factor: 9.079

10.  Serologic survey of Toxoplasma gondii in noncarnivorous free-ranging neotropical mammals in French Guiana.

Authors:  B Carme; C Aznar; A Motard; M Demar; B de Thoisy
Journal:  Vector Borne Zoonotic Dis       Date:  2002       Impact factor: 2.133

View more
  71 in total

1.  Determining UV inactivation of Toxoplasma gondii oocysts by using cell culture and a mouse bioassay.

Authors:  Michael W Ware; Swinburne A J Augustine; David O Erisman; Mary Jean See; Larry Wymer; Samuel L Hayes; J P Dubey; Eric N Villegas
Journal:  Appl Environ Microbiol       Date:  2010-06-11       Impact factor: 4.792

2.  Southeastern Center for Emerging Biologic Threats tabletop exercise: foodborne toxoplasmosis outbreak on college campuses.

Authors:  J Glenn Morris; Allison Greenspan; Kelly Howell; Lisa M Gargano; Joanne Mitchell; Jeffrey L Jones; Morris Potter; Alexander Isakov; Christopher Woods; James M Hughes
Journal:  Biosecur Bioterror       Date:  2012-01-27

3.  When should a trophically and vertically transmitted parasite manipulate its intermediate host? The case of Toxoplasma gondii.

Authors:  Maud Lélu; Michel Langlais; Marie-Lazarine Poulle; Emmanuelle Gilot-Fromont; Sylvain Gandon
Journal:  Proc Biol Sci       Date:  2013-07-03       Impact factor: 5.349

4.  Toxoplasma gondii infection in two captive Patagonian maras.

Authors:  Liv Østevik; Kristoffer R Tysnes; Siv Klevar; John J Debenham
Journal:  J Vet Diagn Invest       Date:  2019-10-24       Impact factor: 1.279

5.  Toxoplasma rhoptry protein 16 (ROP16) subverts host function by direct tyrosine phosphorylation of STAT6.

Authors:  Yi-Ching Ong; Michael L Reese; John C Boothroyd
Journal:  J Biol Chem       Date:  2010-07-12       Impact factor: 5.157

6.  Virulence of Toxoplasma gondii is associated with distinct dendritic cell responses and reduced numbers of activated CD8+ T cells.

Authors:  Elia D Tait; Kimberly A Jordan; Christopher D Dupont; Tajie H Harris; Beth Gregg; Emma H Wilson; Marion Pepper; Florence Dzierszinski; David S Roos; Christopher A Hunter
Journal:  J Immunol       Date:  2010-06-30       Impact factor: 5.422

7.  Genetic and histopathological characterization of Toxoplasma gondii genotypes isolated from free-range chickens reared in the metropolitan region of Rio de Janeiro state, Brazil.

Authors:  Luciana Casartelli-Alves; Sandro Antonio Pereira; Luiz Cláudio Ferreira; Rodrigo de Macedo Couto; Tânia Maria Pacheco Schubach; Maria Regina Reis Amendoeira; Rodrigo Costa da Silva; Hélio Langoni; Patrícia Riddell Millar; Rodrigo Caldas Menezes
Journal:  Parasitol Res       Date:  2021-01-08       Impact factor: 2.289

8.  Hammondia hammondi, an avirulent relative of Toxoplasma gondii, has functional orthologs of known T. gondii virulence genes.

Authors:  Katelyn A Walzer; Yaw Adomako-Ankomah; Rachel A Dam; Daland C Herrmann; Gereon Schares; Jitender P Dubey; Jon P Boyle
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-15       Impact factor: 11.205

9.  Additional haplogroups of Toxoplasma gondii out of Africa: population structure and mouse-virulence of strains from Gabon.

Authors:  Aurélien Mercier; Sébastien Devillard; Barthélémy Ngoubangoye; Henri Bonnabau; Anne-Laure Bañuls; Patrick Durand; Bettina Salle; Daniel Ajzenberg; Marie-Laure Dardé
Journal:  PLoS Negl Trop Dis       Date:  2010-11-02

10.  Immediate Interferon Gamma Induction Determines Murine Host Compatibility Differences between Toxoplasma gondii and Neospora caninum.

Authors:  Rachel S Coombs; Matthew L Blank; Elizabeth D English; Yaw Adomako-Ankomah; Ifeanyi-Chukwu Samuel Urama; Andrew T Martin; Felix Yarovinsky; Jon P Boyle
Journal:  Infect Immun       Date:  2020-03-23       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.